Periodontal tissue regeneration by recombinant human transforming growth factor‐β3 in Papio ursinus

Abstract

Recombinant human transforming growth factor-beta 3 in Matrigel significantly enhanced periodontal tissue regeneration in the nonhuman primate, P. ursinus.

Induction of cementogenesis and periodontal ligament regeneration by recombinant human transforming growth factor‐β3 in Matrigel with rectus abdominis responding cells

“…The following materials were implanted in duplicate: 75 and 125 μg of recombinant transforming growth factor‐β3 in Matrigel ® carrier; and 75 and 125 μg of recombinant transforming growth factor‐β3 reconstituted with insoluble collagenous bone matrix as the carrier. Following heterotopic implantation, class III furcation defects were surgically prepared in the first and second mandibular molars, additionally removing the lingual alveolar bone after preparation of class II furcation defects, as described previously (3,5,8,10–12). To expose the planed root surfaces to periodontal pathogens, the surgically created class III furcation defects were encouraged to enter a chronically inflamed state by implanting 3/0 Vicryl (Ethicon, Somerville, NJ, USA) within the exposed furcations.…”

“…The direct application of recombinant transforming growth factor‐β3 in Matrigel matrix with the addition of rectus abdominis muscle cells vs. the transplantation of fragments of heterotopic ossicles induced by different doses of the transforming growth factor‐β3 protein resulted in highly comparable periodontal tissue regeneration in class II furcation defects of P. ursinus (8).…”

Pre-clinical Models for Oral and Periodontal Reconstructive Therapies

“…Moreover, chronic defects closely resemble those in the human situation, with respect to the microbial flora and the inflammatory reaction (Caton et al, 1994;Karatzas et al, 1999). Surgically created periodontal defects have been used to study the impact of GTR or GBR and the application of biologics, including enamel matrix proteins, BMP-2, FGF-2, TGF-β3, and PDGF (Sculean et al, 1997(Sculean et al, , 2000bRipamonti et al, 2001;Takayama et al, 2001;Donos et al, 2003;Teare et al, 2008). Potential endpoint analyses are generally performed between 3 and 6 mos by measurement of the length and/or area of new attachment, cementum, and bone.…”

Periodontal and Endodontic Regeneration

“…PRP, growth factors including BMPs, PDGF, and EMD are the most commonly used agents (3)(4)(5)(6). Other promising therapeutics include collagen fragments bound to bone grafts, PTH, and transforming growth factor beta 3 (TGF-b3) (70).…”